EBS

#2665
Emergent Biosolutions, Inc.
8.0700 USD
-0.68%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
8.0550
8.1200
1年のレンジ
7.8100
11.4600
1日の変化
-0.68%
月次変化
-24.72%
6か月変化
-24.72%
1年の変化
-24.72%
以前の終値
8.1250
Open
8.0800
Bid
8.0700
Ask
8.0730
Low
8.0550
High
8.1200
ボリューム
356
Open full chart

Financials

Overview 明細書 Statistics
Quarterly Annual
  • Market Capitalization 431.745 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
13.29
Price to sales ratio
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

ニュース